17β-HSD

Cat. No.

A68982

CAS No.

1284180-11-5

AKR1C3-IN-4

AKR1C3-IN-4 is a potent and selective inhibitor of aldo-keto reductase 1C3 (AKR1C3), exhibiting an IC50 value of 0.56 μM. This compound is particularly relevant for investigations into castrate-resistant prostate cancer (CRPC), where AKR1C3 plays a crucial role in tumor progression and hormone regulation. Its mechanism facilitates the exploration of therapeutic strategies targeting metabolic pathways in cancer research.

Cat. No.

A68983

CAS No.

2760791-96-4

17β-HSD1-IN-1

17β-HSD1-IN-1 is a selective inhibitor of 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1), exhibiting IC50 values of 5.6 nM for 17β-HSD1 and 3155 nM for 17β-HSD2. This compound plays a crucial role in modulating estrogen levels and is pertinent for research focused on non-small cell lung cancer (NSCLC). Its specificity enables targeted studies into the enzymatic pathways associated with hormone-driven tumorigenesis.

Cat. No.

A68986

CAS No.

876625-29-5

S07-1066

S07-1066 is a selective inhibitor of aldo-keto reductase 1C3 (AKR1C3) that enhances the cytotoxic effects of doxorubicin (DOX). By inhibiting the AKR1C3-mediated reduction of DOX, S07-1066 effectively reverses drug resistance in cells that overexpress this enzyme. This compound is valuable for research applications investigating chemotherapy resistance and potential adjuvant therapies in cancer treatment.

Cat. No.

A68987

CAS No.

2316765-78-1

17β-HSD10-IN-1

17β-HSD10-IN-1 is a potent inhibitor of 17β-hydroxysteroid dehydrogenase type 10 (17β-HSD10), exhibiting oral bioavailability and effective blood-brain barrier penetration. This compound is characterized by a selective mechanism of action that minimizes off-target effects on mitochondria, along with a favorable safety profile devoid of cytotoxic or neurotoxic effects. It is suitable for research applications focused on disorders related to steroid metabolism and neurodegenerative diseases.

Cat. No.

A68988

CAS No.

2254299-48-2

Linustedastatum

Synonyms: Linustedastat; FOR-6219; OG-6219

Linustedastatum is an orally active inhibitor of hydroxysteroid 17-beta dehydrogenase 1 (HSD17B1). This compound exhibits significant biological activity by modulating the biosynthesis of estrogens, making it a valuable tool for research applications related to endometriosis. Its mechanism of action provides insights into hormonal pathways and potential therapeutic targets in gynecological disorders.

Cat. No.

A68990

CAS No.

863564-24-3

HSD17B13-IN-2

HSD17B13-IN-2 is a selective inhibitor of HSD17B13, demonstrating human IC50 values of 0.18 μM with β-estradiol and 0.25 μM with Leukotriene B4. This compound binds to the active site of HSD17B13 in an NAD+-dependent manner, interacting with the bound NAD+ cofactor to stabilize the HSD17B13 protein and prevent its aggregation. HSD17B13-IN-2 effectively reduces the conversion of β-estradiol to estrone in cellular assays, making it a valuable tool for investigating nonalcoholic fatty liver disease and related metabolic disorders.

Cat. No.

A68992

CAS No.

313259-88-0

HSD17B13-IN-3

HSD17B13-IN-3 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting IC50 values of 0.38 μM and 0.45 μM in biochemical assays using β-estradiol and Leukotriene B4 (LTB4) as substrates, respectively, in the presence of NAD+ as a cofactor. This compound is useful for studying the role of HSD17B13 in steroid metabolism and has potential applications in research related to metabolic disorders and inflammatory conditions. However, it exhibits low cell penetration, which may limit its use in certain cellular assays.

Cat. No.

A68993

CAS No.

2576690-78-1

HSD17B13-IN-9

HSD17B13-IN-9 is a selective inhibitor of 17β-Hydroxysteroid dehydrogenases 13 (HSD17B13), exhibiting an IC50 of 0.01 μM against 50 nM HSD17B13. This compound plays a significant role in the investigation of nonalcoholic fatty liver diseases (NAFLD) by modulating steroid metabolism and related pathways. Its potent inhibitory effects make it a valuable tool for research into hepatic lipid metabolism and associated disorders.

Cat. No.

A68994

CAS No.

2758802-02-5

HSD17B13-IN-8

HSD17B13-IN-8 is an inhibitor of 17β-hydroxysteroid dehydrogenases (HSD17B13), demonstrating potent inhibitory activity with IC50 values of less than 0.1 μM for estradiol and less than 1 μM for LTB3. This compound is primarily utilized in research related to nonalcoholic fatty liver disease (NAFLD), allowing for deeper investigation into the metabolic pathways involved in liver disorders.

Cat. No.

A68996

CAS No.

2576696-23-4

HSD17B13-IN-10

HSD17B13-IN-10 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 value of 0.01 μM. This compound is valuable in researching liver diseases by modulating steroid metabolism and influencing lipid and glucose homeostasis. Its selective inhibition makes it a critical tool for studying the pathogenic mechanisms underlying hepatic disorders.

Cat. No.

A68997

CAS No.

2770246-11-0

HSD17B13-IN-43

HSD17B13-IN-43 is a selective inhibitor of 17β-Hydroxysteroid dehydrogenase type 13 (HSD17B13), exhibiting an IC50 of less than 0.1 μM for estradiol. This compound is valuable for investigating the role of HSD17B13 in nonalcoholic fatty liver disease (NAFLD) and related metabolic disorders. Its ability to modulate steroid metabolism makes it a significant tool for research into liver function and disease mechanisms.

Cat. No.

A68998

CAS No.

1122660-25-6

HSD17B13-IN-41

HSD17B13-IN-41 is a selective inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13). This compound demonstrates potential in modulating pathways associated with liver diseases, metabolic disorders, and cardiovascular conditions, including non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Its application in research can aid in understanding the underlying mechanisms of these diseases and support the development of novel therapeutic strategies.

Cat. No.

A68999

CAS No.

2770246-48-3

HSD17B13-IN-29

HSD17B13-IN-29 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), demonstrating an IC50 value of ≤ 0.1 μM for estradiol. This compound is a valuable tool for research into liver diseases, including non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and drug-induced liver injury (DILI), as well as metabolic and cardiovascular disorders. Its selectivity for HSD17B13 positions it as a significant reagent for investigating therapeutic strategies targeting these conditions.

Cat. No.

A69000

CAS No.

2770246-74-5

HSD17B13-IN-49

HSD17B13-IN-49 is a selective inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 value of ≤ 0.1 μM for estradiol. This compound is valuable for research into various liver-related conditions, including non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), as well as studies on drug-induced liver injury (DILI). Its inhibition of HSD17B13 may provide insights into potential therapeutic strategies for metabolic and cardiovascular disorders linked to liver dysfunction.

Cat. No.

A69001

CAS No.

2770246-16-5

HSD17B13-IN-69

HSD17B13-IN-69 is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an impressive IC50 value of ≤ 0.1 μM for estradiol. This compound is valuable for research into liver diseases, metabolic disorders, and cardiovascular conditions, including non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and drug-induced liver injury (DILI). Its potent inhibition profile makes HSD17B13-IN-69 a crucial tool for exploring therapeutic strategies and understanding disease mechanisms.

Cat. No.

A69002

CAS No.

2912457-83-9

HSD17B13-IN-67

HSD17B13-IN-67 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of less than 0.1 μM for estradiol. This compound is instrumental in studying liver diseases and metabolic disorders, providing valuable insights into the role of HSD17B13 in these conditions. Its high specificity and efficiency make it a useful tool for researchers investigating the therapeutic potential of targeting HSD17B13.

Cat. No.

A69003

CAS No.

2316765-79-2

17β-HSD10-IN-2

17β-HSD10-IN-2 is a selective inhibitor of 17β-hydroxysteroid dehydrogenase type 10 (17β-HSD10), a multifunctional enzyme located in the mitochondria. This compound demonstrates significant inhibition of 17β-HSD10 without causing off-target effects on mitochondrial function or exhibiting cytotoxic and neurotoxic properties. 17β-HSD10-IN-2 is valuable for research applications focused on Alzheimer's disease and hormone-dependent cancers, facilitating the exploration of therapeutic strategies targeting this enzyme.

Cat. No.

A69004

CAS No.

3004661-39-3

HSD17B13-IN-73

HSD17B13-IN-73 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), demonstrating an IC50 value of less than 0.1 μM for estradiol. This compound serves as a valuable tool for investigating the role of HSD17B13 in liver diseases and metabolic disorders, facilitating research into potential therapeutic strategies targeting these conditions.

Cat. No.

A69005

CAS No.

3004660-93-6

HSD17B13-IN-70

HSD17B13-IN-70 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 value of less than 0.1 μM for estradiol. This compound is primarily utilized in research related to liver diseases and metabolic disorders, providing critical insights into the enzymatic regulation of steroid metabolism. HSD17B13-IN-70 serves as a valuable tool for investigators studying the role of HSD17B13 in various biological processes.

Cat. No.

A69006

CAS No.

2849338-44-7

HSD17B13-IN-97

HSD17B13-IN-97 is a highly potent inhibitor of hydroxysteroid 17ß-dehydrogenase 13 (HSD17B13), exhibiting an IC50 value of ≤0.1 µM. This compound holds promise for investigating therapeutic strategies for nonalcoholic fatty liver diseases (NAFLDs), nonalcoholic steatohepatitis (NASH), and drug-induced liver injury (DILI). Its selective inhibition of HSD17B13 makes it a valuable tool for exploring lipid metabolism and liver pathology in preclinical research.

Cat. No.

A69007

CAS No.

948581-46-2

17β-HSD5 inhibitor 3

17β-HSD5 Inhibitor 3 is a selective inhibitor of the enzyme 17β-HSD5, exhibiting an IC50 value of 69 nM. This compound plays a crucial role in modulating steroid metabolism and can be utilized in research related to steroid-related disorders and hormonal regulation. Its oral bioactivity makes it a valuable tool for exploring therapeutic approaches in conditions influenced by 17β-HSD5 activity.

Cat. No.

A69008

CAS No.

2758802-07-0

HSD17B13-IN-15

HSD17B13-IN-15 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), demonstrating an IC50 value of ≤ 1 μM for leukotriene B3 and ≤ 0.1 μM for estradiol. This compound is of significant interest in the study of various liver diseases, including non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), as well as metabolic and cardiovascular disorders. HSD17B13-IN-15 provides valuable insights for research related to drug-induced liver injury (DILI) and potential therapeutic interventions.

Cat. No.

A69009

CAS No.

2848620-87-9

HSD17B13-IN-93

HSD17B13-IN-93 is a selective inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 for estradiol within the range of 0.1 to 0.5 μM. This compound is valuable for investigating the role of HSD17B13 in liver pathologies, metabolic disorders, and cardiovascular conditions, including non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and drug-induced liver injury (DILI). HSD17B13-IN-93 serves as a critical tool for advancing research in these areas.

Cat. No.

A69010

CAS No.

2576696-34-7

HSD17B13-IN-6

HSD17B13-IN-6 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of 0.01 μM. This compound is valuable for investigating the role of HSD17B13 in liver diseases, providing insights that may contribute to the understanding of metabolic disorders and potential therapeutic targets. Researchers can utilize HSD17B13-IN-6 to explore biochemical pathways associated with liver function and disease processes.

Cat. No.

A69012

CAS No.

2225109-18-0

17β-HSD10-IN-3

17β-HSD10-IN-3 is a selective inhibitor of 17β-hydroxysteroid dehydrogenase type 10 (17β-HSD10) with an IC50 value of 5.59 μM. This compound demonstrates a lack of cytotoxicity in the HEK-293 cell line at concentrations up to 20 μM. It is suited for research applications investigating the role of 17β-HSD10 in steroid metabolism and neurodegenerative diseases.